CLAIMS AMENDMENT

1. (currently amended): A compound of the formula

$$A_{n}^{4}A_{n}^{2}A_{n}^{3}A_{n}^{4}A_{n}^{5}A_{n}^{6}A_{n}^{7}A_{n}^{8}A_{n}^{9}A_{n}^{10}A_{n}^{11}A_{n}^{12}A_{n}^{13}A_{n}^{14}A_{n}^{15}A_{n}^{16}A_{n}^{17}A_{n}^{18}$$

$$A_{n}^{1}A_{n}^{2}A_{n}^{3}A_{n}^{4}A_{n}^{6}A_{n}^{$$

and acylated and/or amidated forms thereof,

wherein each n is independently 0 or 1;

A¹, A²[[,]] and A³ are each independently any amino acid;

A⁴, A¹²[[,]] and A¹⁷ are independently acidic amino acids E, D or Q;

 $[A^{13},]]$ $A^{14}[[A^{15}, A^{15}, A^{18}]$ are independently]] is an aromatic amino $[A^{13}, A^{15}]$ acid;

A⁵, A⁷, A⁸, A¹¹, and A¹⁶ represent any amino acid;

 $A^{6}[[,]]$ and $A^{9}[[, and A^{10}]]$ represent independently a basic amino acid or a polar neutral amino acid;

wherein each of said amino acids may be in the L form, racemic form, or D form, with the proviso that

the compound of formula (1) does not comprise ALEAKICHQIEYYFGDF when all amino acids are in the L-form, and

must be in isolated form when all amino acids are in the L-form and formula (1) is of the sequence LDLDTKICEQIEYYFGDF, DDADQRIIKQLEYYFGNI,

VSKLEASTIRQEYYFGDA or QERAIIRQVEYYFGDF.

- 2. (original): The compound of claim 1 wherein all amino acids are gene encoded.
- 3. (currently amended): The compound of claim 1 wherein all linkages between Aⁱ-subunits the amino acids are amide linkages.
- 4. (currently amended): The compound of claim 1 where <u>in</u> all of [[Aⁱ]] <u>the amino</u> acids are in the D form.
- 5. (currently amended): The compound of claim 1 wherein all of [[Aⁱ]] the amino acids are in the L form.

- 6. (original): The compound of claim 1 wherein each of A^4 , A^{12} and A^{17} is independently aspartic or glutamic.
- 7. (currently amended): The compound of claim 1 wherein each of A¹³, A¹⁴[[, A¹⁵ and A¹⁸]] is independently phenylalanine or tyrosine.
 - 8. (canceled)
- 9. (currently amended): The compound of claim 1 wherein each of A⁶[[,]] and A⁹ [[and A¹⁰]] is independently lysine, histidine, arginine, glutamine, or asparagine.
- 10. (previously presented): The compound of claim 1 which is selected from the group consisting of AALEAQICQQIEYYFGDF (SEQ ID NO:2), AALQAKICHQIQYYFGQF (SEQ ID NO:3), QQQEAKICHQIEYYFGDF (SEQ ID NO:4) and AALEAKICHQIEYQFGDF (SEQ ID NO:12).
- 11. (currently amended): The compound of claim 1 which is in isolated or purified form and is selected from the group consisting of ALEAKICHQIEYYFGDF (SEQ ID NO:13), AALEAKICHQIEYYFGDF (SEQ ID NO:14), LDLDTKICEQIEYYFGDF (SEQ ID NO:15), AALEAKICHQIEEYYFGDF (SEQ ID NO:16), DDADQRIIKQLEYYFGNI (SEQ ID NO:17), VSKLEASTIRQEYYFGDA (SEQ ID NO:18) and QERAIIRQVEYYFGDF (SEQ ID NO:19).
- 12. (original): A pharmaceutical, veterinary or agricultural/horticultural composition which comprises the compound of claim 1 along with a suitable excipient.

13-19. (canceled)

20. (original, withdrawn): A method to treat viral infection in a plant or animal subject which method comprises administering to said subject an antivirally effective amount of the compound of claim 1.

- 21. (original, withdrawn): The method of claim 20 wherein said method further comprises administering at least one additional antiviral agent.
- 22. (original, withdrawn): The method of claim 21 wherein said administering of the compound and said at least one additional antiviral agent is substantially simultaneous.
- 23. (original, withdrawn): The method of claim 21 wherein said administering of the compound of claim 1 and said at least one antiviral compound is sequential.
- 24. (original, withdrawn): The method of claim 21 wherein said additional antiviral compound is I-RNA.

25-35. (canceled)